We now provide human proteomic data indicating that CLIC4 expression levels and those of members of the TGF-β pathway in breast cancer patients are highly correlated implying that CLIC4 levels could serve as a surrogate TGF-β effector of TGF-β-driven pathologies. This evidence concerns the gene TGFB1 and breast carcinoma.